Elevance Health, Inc. (ELV): analysis and signal as of September 4, 2026

Published on September 5, 2026 at 08:03 · Updated on September 5, 2026 at 08:03 · by Aurélien Ambert, QDNA

Exchange : NYSE · Sector : Health Services

In short

The signal is weak, with an internal vote of 3 out of 3, for lack of a net catalyst across all layers. The main reason lies in the 1,38 % cost of movement, the deterioration in operating margin and the unavailable data, which do not allow the case to be validated.

Current signal: weak (vote 3/3)
Deterministic score: -0.5 → signal expected by the scale : weak (September 10, 2026)
Layers: fundamentals : neutral, price : positive, risks : neutral

Triggered rules

Rule	Weight
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

The technical layer in isolation is positive, but the fundamentals show an operating margin compression from 5,6 % to 3,8 % between FY 2023 and TTM June 2026, with net income falling from 5,987 Md to 4,963 Md USD. The risk layer and the sentiment layer remain neutral, and the volume of data marked « périmé possible » or missing adds to the 1,38 % cost of movement, preventing the construction of a sufficient safety margin in the current configuration.

Bull case

The technical convergence is marked: intraday drift at +6,9 bp/day versus overnight at -9,2 bp/day, positive half-year cumulative return over both windows, price as of 03/09/2026 at +4,8 % above the 50-session moving average and +16,2 % above the 200-session moving average. The « expansion » macro regime favors defensive healthcare. Starboard activism, with a stake disclosed in February 2024 and more than 2 Md USD in claimed efficiency gains, as well as the Anthem 360 plan, with 4 Md USD in administrative cost reductions, open an upside option through operational execution, without any immediate bearish catalyst over the short window.

Bear case

The case is operationally degraded: the 6,27 % TTM revenue growth is entirely driven by the Carelon and Paragon acquisitions. Querying the SEC EDGAR database returns HTTP 403, which prevents reading the FY 2025 10-K, the T2 2026 10-Q, the Beneish and Altman scores, free cash flow and net debt. Sector headwinds are added with the V28 revision of the CMS Medicare Advantage risk model, pressure on the medical ratio, opioid litigation, board transition after the departure of Gail Boudreaux, and a two-year closed window showing -40,7 % overnight.

Scenarios

The probability of a bullish scenario is 25 %, with a +20 % target over twelve months, assuming credible execution of Anthem 360, absorption of the V28 revision and a stabilization of the operating margin around 4 %. The central scenario, at 50 %, expects an oscillation from -8 % to +10 %, with defensive carry provided by the quarterly dividend in the range of 1,60 to 1,70 USD per share. The bearish scenario, at 25 %, sets a maximum loss of -30 %, triggered by a punitive V28 revision, an increase in the medical ratio, a goodwill impairment on Paragon or increased litigation.

Risks

The main risks relate to operational execution: the V28 revision of the CMS Medicare Advantage model may prove punitive, the medical ratio may remain under pressure, and Paragon weighs on the balance sheet through a goodwill exposure that could be impaired. The management transition after the departure of Gail Boudreaux, opioid litigation and the impossibility of accessing the audited financial statements for lack of an EDGAR response constitute additional analytical constraints. A change to the « expansion » macro regime, although presented as favorable to defensive healthcare, would highlight the fragility of the case even more.

Market positioning (short sellers)

Short interest / shares outstanding: 2.50 %
Days to cover: 5.67
Settlement date: 2026-08-14
Source: FINRA (disseminated on 2026-08-26)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	No change: first formalized verdict on ELV, deterministic signal of weighted rules at +0,00, one analysis layer out of three positive, no new quantified fact since the last state of record. This text is provided for information purposes.

Frequently asked questions

What are the reasons for the weak signal despite positive technical indicators?

The signal is weak because only one analysis layer out of three is positive. The fundamentals show an operating margin going from 5,6 % to 3,8 % and a net income down from 5,987 to 4,963 Md USD. The risk layer and the sentiment layer remain neutral, the cost of movement is 1,38 %, and missing data or data marked « périmé possible » prevent a complete validation.

Why is the SEC EDGAR block presented as an obstacle?

The HTTP 403 error on the EDGAR database prevents consultation of the documents filed by the company, in particular the annual 10-K form 2025 and the 10-Q form for the second quarter of 2026. The analysis can therefore calculate neither the Beneish score, the Altman score, free cash flow nor net debt. This unavailability blocks any forensic verification of the accounts.

What do the efficiency gains attributed to Starboard and to the Anthem 360 plan encompass?

The Starboard stake, disclosed in February 2024, is associated with more than 2 Md USD in claimed efficiency gains. The Anthem 360 plan provides for 4 Md USD in administrative cost reductions. These two mechanisms are presented as an upside lever through operational execution, subject to an operating margin stabilizing around 4 % and a satisfactory absorption of the V28 revision of the CMS Medicare Advantage risk model.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

September 10, 2026 — 7.01 Regulation FD Disclosure (SEC · 8-K)
July 15, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
July 15, 2026 — 10-Q (SEC · 10-Q)
June 10, 2026 — 7.01 Regulation FD Disclosure (SEC · 8-K)
May 13, 2026 — 5.07 Submission of Matters to a Vote of Security Holders (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 5, 2026 at 08:03 (UTC).
Interests: no position in the stock analysed (ELV) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.